Helps diagnose coronary artery disease. Sold as Thallous Chloride Tl 201. Every FDA application for this active ingredient: 4 branded and 2 generic.
As of Nov 16, 2026, FDA lists 6 applications for Thallous Chloride TL-201 (sold as Thallous Chloride Tl 201), first approved Dec 16, 1977, with 5 new uses approved and 0 published complete response letters.
| Dec 16, 1977 | Thallous Chloride Tl 201NDA 17806 · New molecular entity | Lantheus Medcl | 22 | Discontinued |
| Oct 23, 1979 | Thallous Chloride Tl 201NDA 18150 · New formulation or manufacturer | Curium | 17 | Marketed |
| Feb 1, 1982 | Thallous Chloride Tl 201NDA 18110 · New formulation or manufacturer | Ge Healthcare | 12 | Discontinued |
| Dec 30, 1982 | Thallous Chloride Tl 201NDA 18548 · New formulation or manufacturer | Bracco | 6 | Discontinued |
| Nov 21, 2001 | Thallous Chloride Tl 201ANDA 75569 | Trace Life | 2 | Discontinued |
| Nov 9, 2006 | Thallous Chloride Tl 201ANDA 77698 | Curium | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA